Page 1 | Search Results | Blood | American Society of Hematology

1-6 of 6

Sort by

Sort Order Select

Journal Articles

Comparative Analysis of Clinical Trial Outcomes between African American and White Patients Treated with Lenalidomide and Dexamethasone for Multiple Myeloma (MM)

Sikander Ailawadhi, Gail Larkins, RN, MBA, Weiyuan Chung, Shankar Srinivasan, PhD, Amit Agarwal, MD PhD

Blood (2017) 130 (Supplement 1): 3428.

https://doi.org/10.1182/blood.V130.Suppl_1.3428.3428

Published: 2017

Journal Articles

Development of a Predictive Model of Multiple Myeloma (MM) Patient (pt) Outcomes Based on Treatment Class Transitions Using the Connect ® MMpatient Registry

Sundar Jagannath, MD, Robert M. Rifkin, MD, Cristina J. Gasparetto, MD, Kathleen Toomey, MD, Brian G. M. Durie, MD, James W. Hardin, PhD, Howard R. Terebelo, DO, Lynne Wagner, PhD, Mohit Narang, MD, Shankar Srinivasan, PhD, Ahmed YoussefAgha, PhD, Amani Kitali, MBA, MPH, Gail Larkins, RN, MBA, Amit Agarwal, MD PhD, Rafat Abonour, MD

Blood (2017) 130 (Supplement 1): 3122.

https://doi.org/10.1182/blood.V130.Suppl_1.3122.3122

Published: 2017

Journal Articles

Treatment Outcomes with Pomalidomide (POM) in Combination with Low-Dose Dexamethasone (LoDex) in Patients with Relapsed and Refractory Multiple Myeloma (RRMM) and Del(17p13) and/or t(4;14)(p16;q32) Cytogenetic Abnormalities Who Have Received Prior Therapy with Lenalidomide (LEN) and Bortezomib (BORT)

Paul G. Richardson, MD, Andrzej Jakubowiak, MD, PhD, Nizar J. Bahlis, MD, David S. Siegel, MD, PhD, Christine I. Chen, MD, Min Chen, PhD, Mohamed Zaki, MD, Gail Larkins, RN, Kenneth C. Anderson, MD

Blood (2012) 120 (21): 4053.

https://doi.org/10.1182/blood.V120.21.4053.4053

Published: 2012

Journal Articles

Pomalidomide (POM) with Low-Dose Dexamethasone (LoDEX) in Patients with Relapsed and Refractory Multiple Myeloma (RRMM): Outcomes Based on Prior Treatment Exposure

Ravi Vij, MD, Craig C. Hofmeister, MD, Paul G. Richardson, MD, Sundar Jagannath, MD, David S. Siegel, MD, PhD, Rachid Baz, MD, Min Chen, PhD, Mohamed Zaki, MD, Gail Larkins, RN, Kenneth C. Anderson, MD

Blood (2012) 120 (21): 4070.

https://doi.org/10.1182/blood.V120.21.4070.4070

Published: 2012

Journal Articles

Randomized, Open Label Phase 1/2 Study of Pomalidomide (POM) Alone or in Combination with Low-Dose Dexamethasone (LoDex) in Patients (Pts) with Relapsed and Refractory Multiple Myeloma Who Have Received Prior Treatment That Includes Lenalidomide (LEN) and Bortezomib (BORT): Phase 2 Results

Paul G. Richardson, MD, David S. Siegel, MD, PhD, Ravi Vij, MD, Craig C. Hofmeister, MD, Sundar Jagannath, MD, Christine Chen, MD, Sagar Lonial, MD, Andrzej J Jakubowiak, MD, PhD, Nizar J Bahlis, MD, Rachid Baz, MD, Gail Larkins, RN, Min Chen, PhD, Mohamed Zaki, MD, PhD, Kenneth C. Anderson, MD

Blood (2011) 118 (21): 634.

https://doi.org/10.1182/blood.V118.21.634.634

Published: 2011

Journal Articles

A Phase 1/2 Multi-Center, Randomized, Open Label Dose Escalation Study to Determine the Maximum Tolerated Dose, Safety, and Efficacy of Pomalidomide Alone or In Combination with Low-Dose Dexamethasone In Patients with Relapsed and Refractory Multiple Myeloma Who Have Received Prior Treatment That Includes Lenalidomide and Bortezomib

Paul G Richardson, MD, David Siegel, MD, PhD, Rachid Baz, MD, Susan L. Kelley, MD, Nikhil C. Munshi, MD, Daniel Sullivan, MD, Melissa Alsina, MD, Deborah Doss, RN, OCN, Laura McBride, Gail Larkins, RN, Maria Lizza, BS, Xin Yu, Mohamed Zaki, MD, Christian J. Jacques, MD, Kenneth C. Anderson, MD

Blood (2010) 116 (21): 864.

https://doi.org/10.1182/blood.V116.21.864.864

Published: 2010

NARROW

Comparative Analysis of Clinical Trial Outcomes between African American and White Patients Treated with Lenalidomide and Dexamethasone for Multiple Myeloma (MM)

Development of a Predictive Model of Multiple Myeloma (MM) Patient (pt) Outcomes Based on Treatment Class Transitions Using the Connect ® MMpatient Registry

Pomalidomide (POM) with Low-Dose Dexamethasone (LoDEX) in Patients with Relapsed and Refractory Multiple Myeloma (RRMM): Outcomes Based on Prior Treatment Exposure

Randomized, Open Label Phase 1/2 Study of Pomalidomide (POM) Alone or in Combination with Low-Dose Dexamethasone (LoDex) in Patients (Pts) with Relapsed and Refractory Multiple Myeloma Who Have Received Prior Treatment That Includes Lenalidomide (LEN) and Bortezomib (BORT): Phase 2 Results

Email alerts

ASH Publications

American Society of Hematology

Comparative Analysis of Clinical Trial Outcomes between African American and White Patients Treated with Lenalidomide and Dexamethasone for Multiple Myeloma (MM)

Development of a Predictive Model of Multiple Myeloma (MM) Patient (pt) Outcomes Based on Treatment Class Transitions Using the Connect ® MMpatient Registry

Pomalidomide (POM) with Low-Dose Dexamethasone (LoDEX) in Patients with Relapsed and Refractory Multiple Myeloma (RRMM): Outcomes Based on Prior Treatment Exposure

Randomized, Open Label Phase 1/2 Study of Pomalidomide (POM) Alone or in Combination with Low-Dose Dexamethasone (LoDex) in Patients (Pts) with Relapsed and Refractory Multiple Myeloma Who Have Received Prior Treatment That Includes Lenalidomide (LEN) and Bortezomib (BORT): Phase 2 Results

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only